Engineered bacterial outer membrane vesicles integrated with photothermal therapy: disrupting the CD47-SIRPα axis to enhance pyroptosis and antitumor immunity
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Bacterial outer membrane vesicles (OMVs) garner significant attention in tumor therapy due to their unique ability to selectively target and eliminate tumor cells. However, tumor cells commonly overexpress CD47, a “don’t eat me” signal that interacts with signal regulatory protein alpha (SIRPα) on macrophages, thus evading immune clearance. Enhancing OMV-induced immunogenicity and reprogramming macrophages toward a pro-phagocytic phenotype while blocking the CD47-SIRPα pathway is essential. In this study, OMVs are engineered to express anti-CD47 antibodies on their surface and are combined with Y18 nanoparticles (NPs) to construct a biomimetic hybrid nanoplatform (Y18-OMV NPs). This dual-functional strategy integrates photothermal design and immune checkpoint blockade to achieve efficient photoimmunotherapy. Photothermal therapy (PTT) induces immunogenic cell death via endoplasmic reticulum stress (eIF2α-ATF4-CHOP pathway) and pyroptosis (NLRP3/Caspase-1/GSDMD axis), releasing damage-associated molecular patterns (DAMPs) to activate immune responses. Simultaneously, Y18-OMV NPs function as immune adjuvants to repolarize M2-like tumor-associated macrophages (TAMs) into the M1 phenotype, enhance macrophage-mediated phagocytosis, promote dendritic cell maturation, and activate T cell infiltration. This strategy also downregulates heat shock proteins (HSPs), reduces thermotolerance, and enhances PTT efficacy. Overall, this approach provides robust photothermal-immunotherapy synergy and offers a promising direction for CD47-targeted clinical tumor immunotherapy. Diagrammatic representation of the preparation of Y18-OMV NPs and their antitumor mechanisms.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Engineered bacterial outer membrane vesicles integrated with photothermal therapy: disrupting the CD47-SIRPα axis to enhance pyroptosis and antitumor immunity
- Date Crossref
- 27/08/2026
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Guangdong Pharmaceutical University Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations pays non établi dans la noticeUniversité ou école supérieure
-
Southern Medical University Shenzhen Hospital pays non établi dans la noticeÉtablissement de santé
-
Shenzhen Second People's Hospital pays non établi dans la noticeÉtablissement de santé
-
Guangdong Medical College pays non établi dans la noticeUniversité ou école supérieure
-
Chinese Academy of Medical Sciences & Peking Union Medical College pays non établi dans la noticeUniversité ou école supérieure
-
Shenzhen People’s Hospital (The Second Clinical Medical College Department of Nephrology pays non établi dans la noticeUniversité ou école supérieure
-
Affiliated Hospital of Guangdong Medical University Guangdong Provincial Key Laboratory of Autophagy and Major Chronic Non-communicable Diseases pays non établi dans la noticeUniversité ou école supérieure
-
State Key Laboratory for Quality Ensurance and Sustainable Use of Dao-di Herbs pays non établi dans la noticeStructure de recherche
Guangdong Provincial Key Laboratory for Research and Evaluation of Pharmaceutical Preparations — Guangdong Pharmaceutical University, Southern Medical University Shenzhen Hospital et Shenzhen Second People's Hospital, avec 5 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.